View More Recent Stories

Jan 6, 2025 04:31PM Denali Therapeutics' (DNLI) Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Did Not Meet Endpoints
Dec 16, 2024 04:48AM Stifel Upgrades Denali Therapeutics Inc. (DNLI) to Buy
Nov 12, 2024 01:05PM Denali Therapeutics Inc. (DNLI) PT Raised to $34 at BofA Securities
Nov 1, 2024 05:46AM Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies
Oct 14, 2024 06:04AM BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Oct 11, 2024 08:45AM TD Cowen Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Sep 4, 2024 05:26AM Denali Therapeutics Inc. (DNLI) PT Raised to $29 at BofA Securities
Sep 3, 2024 11:58AM B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Sep 3, 2024 11:46AM Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Sep 3, 2024 10:22AM Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
Sep 3, 2024 08:02AM Denali Therapeutics (DNLI) Announces Successful Meeting with the FDA, Plans to File for Accelerated Approval of Tividenofusp Alfa
Aug 14, 2024 02:01PM Denali Therapeutics (DNLI) Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform
Aug 2, 2024 06:48AM Denali Therapeutics Inc. (DNLI) PT Lowered to $90 at H.C. Wainwright
Aug 1, 2024 08:51AM Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c
View More Recent Stories